(1)教育背景

2020.09-至今 博士研究生  

2019.03-2020.08 中国科学院上海药物研究所  助理研究员 

2018.07-2019.02 四川科伦药物研究院  制剂研究员 

2016.09-2018.06 中国药科大学 硕士研究生

2012.09-2016.06 中国药科大学 学士 

(2)研究方向：智能递药系统 

(3)发表论文情况:

[1] Gao J, Hou B, Zhu Q, Yang L, Jiang X, Zou Z, Li X, Xu T, Zheng M, Chen YH, Xu Z, Xu H, Yu H. Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy. Nat Commun. 2022 Jul 26;13(1):4318.

[2] Gao J#, Zhang H#, Zhou F, Hou B, Chen M, Xie Z, Yu H, Acid-activatible micelleplex delivering siRNA-PD-L1 for improved cancer immunotherapy of CDK4/6 inhibition, Chinese Chemical Letters, 2021, 32(6), 1929-1936.

[3] Gao J, Wang W, Pei Q. et al. Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy. Acta Pharmacol Sin 2020, 41, 986–994.

[4] Zhou F#, Gao J#, Xu Z, Li T, Gao A, Sun F, Wang F, Wang W, Geng Y, Zhang F, Xu Z, Yu H, Overcoming immune resistance by sequential prodrug nanovesicles for promoting chemoimmunotherapy of cancer, Nano Today, 2021, 36, 101025.

[5] Zhou F#, Gao J#, Tang Y, Zou Z, Jiao S, Zhou Z, Xu H, Xu Z, Yu H, Xu Z, Engineering Chameleon Prodrug Nanovesicles to Increase Antigen Presentation and Inhibit PD-L1 Expression for Circumventing Immune Resistance of Cancer. Advcance. Materials. 2021, 33, 2102668.

[6] Yang B#, Gao J#, Pei Q#, Xu H, Yu H. Engineering Prodrug Nanomedicine for Cancer Immunotherapy. Adv Sci. 2020 Oct 25;7(23):2002365.

[7] Jing Gao, Lei Yang, Shumin Lei, Feng Zhou, Huijun Nie, Tianfeng Xu, Xiaohua Chen, Xiaobao Yang, Chunquan Sheng, Yu Rao, Kanyi Pu, Jian Jin, Zhiai Xu, Haijun Yu*. Stimuli-activatable PROTAC for precise protein degradation and cancer therapy. Science Bulletin. 2023, 68, 1069-1085.

(4)获奖情况:

第四届“新光闪药”研究生学术年会---优秀奖

第十届“创业江苏”科技创业大赛---团队组二等奖

第十五届 中国药物制剂大会“药剂学研究生报告” ---第二名